tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market
ALLO
Allogene Therapeutics
RESEARCH TOOLSreports
Want to see ALLO full AI Analyst Report?

Allogene Therapeutics (ALLO) Ratios

1,832 Followers

Allogene Therapeutics Ratios

ALLO's free cash flow for Q2 2026 was $1.00. For the 2026 fiscal year, ALLO's free cash flow was decreased by $ and operating cash flow was $-9.12. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 10.72 7.93 8.54 12.38 9.84
Quick Ratio
 10.72 7.93 8.54 12.38 9.84
Cash Ratio
 1.22 1.59 2.12 2.24 1.15
Solvency Ratio
 -1.35 -1.45 -1.93 -2.40 -2.11
Operating Cash Flow Ratio
 -3.22 -4.59 -5.64 -6.41 -4.10
Short-Term Operating Cash Flow Coverage
 0.00 0.00 0.00 0.00 0.00
Net Current Asset Value
$ 226.08M$ 134.39M$ 176.85M$ 328.51M$ 374.13M
Leverage Ratios
Debt-to-Assets Ratio
 0.13 0.20 0.17 0.15 0.12
Debt-to-Equity Ratio
 0.16 0.28 0.21 0.19 0.15
Debt-to-Capital Ratio
 0.14 0.22 0.18 0.16 0.13
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.26 1.42 1.30 1.25 1.23
Debt Service Coverage Ratio
 -117.33 -165.07 -1.35K 0.00 0.00
Interest Coverage Ratio
 -138.71 -192.50 -1.51K 0.00 0.00
Debt to Market Cap
 0.00 0.00 0.00 0.00 0.00
Interest Debt Per Share
 0.22 0.38 0.47 0.61 0.71
Net Debt to EBITDA
 -0.21 -0.18 -0.06 -0.04 -0.12
Profitability Margins
Gross Profit Margin
-699.35%0.00%100.00%100.00%-9063.46%
EBIT Margin
-3538.66%0.00%-1168027.27%-344489.47%-215087.18%
EBITDA Margin
-3287.20%0.00%-1106031.82%-329543.16%-205923.72%
Operating Profit Margin
-3886.14%0.00%-1241813.64%-344986.32%-215087.18%
Pretax Profit Margin
-3566.68%0.00%-1168850.00%-344489.47%-218214.10%
Net Profit Margin
-3566.68%0.00%-1170863.64%-344489.47%-218214.10%
Continuous Operations Profit Margin
-3566.68%0.00%-1170863.64%-344489.47%-218214.10%
Net Income Per EBT
100.00%100.00%100.17%100.00%100.00%
EBT Per EBIT
91.78%92.25%94.12%99.86%101.45%
Return on Assets (ROA)
-30.08%-45.90%-46.94%-50.91%-41.43%
Return on Equity (ROE)
-50.04%-65.25%-61.01%-63.89%-51.05%
Return on Capital Employed (ROCE)
-34.79%-53.97%-53.24%-54.10%-43.70%
Return on Invested Capital (ROIC)
-34.79%-52.84%-52.47%-53.51%-43.36%
Return on Tangible Assets
-30.08%-45.90%-46.94%-50.91%-41.43%
Earnings Yield
-28.27%-63.15%-62.08%-64.97%-37.81%
Efficiency Ratios
Receivables Turnover
 0.00 0.00 0.01 0.06 0.00
Payables Turnover
 6.22 2.89 0.00 0.00 1.03
Inventory Turnover
 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.04 0.00 <0.01 <0.01 <0.01
Asset Turnover
 <0.01 0.00 <0.01 <0.01 <0.01
Working Capital Turnover Ratio
 0.02 0.00 <0.01 <0.01 <0.01
Cash Conversion Cycle
 -58.69 -126.11 31.52K 6.53K -354.66
Days of Sales Outstanding
 0.00 0.00 31.52K 6.53K 0.00
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 58.69 126.11 0.00 0.00 354.66
Operating Cycle
 0.00 0.00 31.52K 6.53K 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.31 -0.68 -1.03 -1.51 -1.54
Free Cash Flow Per Share
 -0.31 -0.68 -1.03 -1.52 -1.58
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 0.04
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.01 1.02
Dividend Paid and CapEx Coverage Ratio
 -254.22 -386.65 -288.62 -156.82 -42.48
Capital Expenditure Coverage Ratio
 -254.22 -386.65 -288.62 -156.82 -42.48
Operating Cash Flow Coverage Ratio
 -1.45 -1.79 -2.21 -2.50 -2.18
Operating Cash Flow to Sales Ratio
 -22.02 0.00 -9.10K -2.50K -1.41K
Free Cash Flow Yield
-16.70%-49.51%-48.44%-47.49%-25.07%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -2.66 -1.57 -1.61 -1.54 -2.64
Price-to-Sales (P/S) Ratio
 132.41 0.00 18.86K 5.30K 5.77K
Price-to-Book (P/B) Ratio
 1.34 1.03 0.98 0.98 1.35
Price-to-Free Cash Flow (P/FCF) Ratio
 -5.99 -2.02 -2.06 -2.11 -3.99
Price-to-Operating Cash Flow Ratio
 -5.73 -2.03 -2.07 -2.12 -4.08
Price-to-Earnings Growth (PEG) Ratio
 -0.05 0.05 0.04 0.13 -0.03
Price-to-Fair Value
 1.34 1.03 0.98 0.98 1.35
Enterprise Value Multiple
 -4.24 -1.88 -1.77 -1.65 -2.92
Enterprise Value
 646.10M 333.82M 430.49M 515.72M 939.61M
EV to EBITDA
 -4.24 -1.88 -1.77 -1.65 -2.92
EV to Sales
 139.25 0.00 19.57K 5.43K 6.02K
EV to Free Cash Flow
 -6.30 -2.23 -2.14 -2.16 -4.16
EV to Operating Cash Flow
 -6.32 -2.24 -2.15 -2.17 -4.26
Tangible Book Value Per Share
 1.33 1.33 2.17 3.26 4.66
Shareholders’ Equity Per Share
 1.33 1.33 2.17 3.26 4.66
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 >-0.01 0.00 0.00
Revenue Per Share
 0.01 0.00 <0.01 <0.01 <0.01
Net Income Per Share
 -0.50 -0.87 -1.32 -2.09 -2.38
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 1.01 1.01 1.00 1.00 1.01
Research & Development to Revenue
 25.79 0.00 8.74K 2.56K 1.64K
SG&A to Revenue
 13.46 0.00 2.96K 754.45 508.37
Stock-Based Compensation to Revenue
 8.08 0.00 2.35K 694.22 535.90
Income Quality
 0.62 0.78 0.78 0.73 0.66
Currency in USD